BCL2 and adenocarcinoma: The adenocarcinoma cohort was also analysed in relation to several other previously suggested CRCa biomarkers: hERG1 and KCa3.1 (potassium channels); carbonic anhydrase IX (CA IX); vascular endothelial growth factor-A (VEGF-A); glucose transporter 1 (Glut1); Ki67; P53; BCL2 and epidermal growth factor receptor (EGFR).